Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA5 | P11021 | 1/20 | 0.47 |
| ▸ | ACLY | P53396 | 8/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.44 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6407734 | 0.88 | HSPA5 (0.51) | HSPA5ACLYGRIK1MEN1KMT2A | |
| SCHEMBL6414621 | 0.84 | HSPA5 (0.48) | HSPA5ACLY | |
| SCHEMBL6410292 | 0.83 | HSPA5 (0.62) | HSPA5ACLYMEN1KMT2A | |
| SCHEMBL6407663 | 0.81 | NPC1 (0.50) | HSPA5KCNMA1GRIK1MEN1KMT2A | |
| SCHEMBL6408135 | 0.79 | KCNMA1 (0.55) | HSPA5KCNMA1MEN1KMT2A | |
| SCHEMBL6410312 | 0.77 | KCNMA1 (0.52) | HSPA5ACLYTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL4345397 | 0.75 | TRPV1 (0.58) | GRIK1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL6411984 | 0.74 | HSPA5 (0.47) | HSPA5ACLYKCNMA1MEN1KMT2A | |
| SCHEMBL6407982 | 0.74 | HSPA5 (0.44) | HSPA5ACLYKCNMA1MEN1KMT2A | |
| SCHEMBL6413565 | 0.72 | HSPA5 (0.61) | HSPA5ACLYMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124667-A1 | Oxamide inhibitors of plasminogen activator inhibitor-1 | CEREP SA (FR) | 2005-06-09 | — | — | US | claimed |
| US-20050124667-A1 | Oxamide inhibitors of plasminogen activator inhibitor-1 | CEREP SA (FR) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124667-A1 | Oxamide inhibitors of plasminogen activator inhibitor-1 | SERPINE1, SERPINC1, SERPINB1 | HSPA5 4261/4885ACLY 2109/4885TAS1R3 2771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.